Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 2/20 | 0.39 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | DNM2 | P50570 | 7/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777536 | 0.91 | KCNH2 (0.40) | KCNH2NCF1RAD52POLBSMARCA2 | |
| SCHEMBL6676375 | 0.87 | KCNH2 (0.42) | KCNH2POLBHTTSMN1; SMN2 | |
| SCHEMBL6677689 | 0.86 | KCNH2 (0.35) | KCNH2DNM2 | |
| SCHEMBL2776366 | 0.86 | SCN9A (0.42) | NCF1KDM1ARCOR1EHMT2 | |
| SCHEMBL6673922 | 0.85 | DNM2 (0.37) | KCNH2NCF1RAD52DNM2KDM1A | |
| SCHEMBL6679132 | 0.84 | KDM4E (0.48) | POLBSLC2A1 | |
| SCHEMBL6677683 | 0.84 | KCNH2 (0.36) | KCNH2NCF1DNM2KDM1ARCOR1 | |
| SCHEMBL2776640 | 0.84 | KDM1A (0.42) | RAD52POLBKDM1ARCOR1EHMT2 | |
| SCHEMBL6679102 | 0.84 | FLT3 (0.39) | KCNH2NCF1DNM2KDM1ARCOR1 | |
| SCHEMBL6679202 | 0.83 | KCNH2 (0.42) | KCNH2NCF1RAD52KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816521-B2 | 1,2,4-benzotriazine-1,4-dioxides | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-10-19 | — | — | US | disclosed |
| US-7816521-B2 | 1,2,4-benzotriazine-1,4-dioxides | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-10-19 | — | — | US | disclosed |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
| EP-1468688-A2 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | Auckland Uniservices Limited (NZ) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192686-A1 | Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments | NPM1, DUOX1, NOX5 | KCNH2 2400/4885NCF1 100/4885RAD52 2135/4885 |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | HIF1AN, HIF1A, HYOU1 | KCNH2 406/4885NCF1 2134/4885RAD52 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.